Stack
Analyzer

Choose the combination you use; See interaction & security auditing, function axis coverage and redundancy/gap notes on a single screen.

Substances in combination

Maximum 8 items. Your selection is saved in the link; you can share.

Interaction & security

  • medium riskDMAE

    DMAE - dikkat

    Fisman 1981: A double-blind placebo-controlled trial studied 27 people with Alzheimer's disease. 6 of 13 in the drug group withdrew within 5 weeks because of side effects; no significant benefit was found. Reported problems included drowsiness, slowing, increased confusion and mild blood-pressure elevation. The abstract does not verify randomization; 6/13 is not the adverse-event rate for all users. It does not justify self-directed dose reduction or timing advice. Fisher 2001: Mouse embryos exposed in vitro to 250–750 µM DMAE for 26 hours developed facial and neural-tube defects. This is not an oral-dose trial in pregnant humans; human risk magnitude or a safe dose cannot be calculated. It gives no reassurance for self-use in pregnancy. Use with neurological/psychiatric illness or medicines needs clinical assessment; missing interaction records do not mean safe.

Combination profile

Functional axis coverage

Cognitive ·1EnergysleepMoodneurotrophic

Source distribution

Yarı-sentetik ×1

These results are screening warnings. Severity describes a potential concern, not its probability or the certainty of clinical evidence. Some rules extrapolate from mechanisms or drug classes; an absent warning does not establish safety.

Looking for a new combination? Start from a goal with the Nootropic Finder or browse the ready-made stacks.

FDA: Mixing Medications and Dietary Supplements Can Endanger Your Health